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Summary
Objective: Published studies have tested over 90 genes for association with osteoarthritis (OA), but few positives reported have been
independently replicated. Using a new caseecontrol study, our aim was to attempt the replication of ﬁndings from 12 genes reported to
have signiﬁcant genetic association with OA and to further examine the role of genetic variation in six of these genes.
Methods: A caseecontrol study was undertaken in Nottingham, UK. Hospital-referred index cases with symptomatic, radiographic OA (ROA)
of the knee (n¼ 1040) or hip (n¼ 1004) were recruited. Asymptomatic controls (n¼ 1123) were recruited from intravenous urography waiting
lists and screened for radiographic hip and knee OA. Sixty-eight polymorphisms were genotyped in IL1A, IL1B, IL1RN, IL4R, IL6, COL2A1,
ADAM12, ASPN, IGF1, TGFB1, ESR1 and VDR. Statistical analysis compared allele or genotype frequencies of these polymorphisms in all
asymptomatic controls and the subset of controls without ROA vs all OA, knee OA and hip OA. The analyses were adjusted for age, gender
and body mass index.
Results: We were unable to replicate any of the published genetic associations investigated. Our extended exploratory analyses identiﬁed
some associations between polymorphisms in TGFB1, IGF1 and IL1RN and OA; but the strength of evidence varied with the control group
used.
Conclusion: Lack of replication is common and could be due to differences in study design, phenotype, populations examined or the occur-
rence of false positives in the initial study. Variants within TGFB1, IGF1 and IL1RN could have a role in OA susceptibility; however, replication
of these ﬁndings is required in an independent study.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis and
is characterised by the progressive loss of articular cartilage
and changes in the adjacent bone. Important risk factors for
OA include obesity, previous injury and biomechanical fac-
tors such as muscle weakness and joint malalignment and
to a lesser extent occupation, physical activity, bone mineral
density and hormone replacement therapy1.
Evidence from family and twin studies has also identiﬁed
a genetic component to OA2e5. Linkage scans, as well as
association studies of over 90 different genes, have attemp-
ted to elucidate the genes in which genetic variation contrib-
utes to OA susceptibility and disease progression. The
most widely studied of these include COL2A1, the gene
for the major collagen, in cartilage (type IIA), oestrogen*Address correspondence and reprint requests to: Dr Rose A.
Maciewicz, Ph.D., Chief Scientist, Respiratory & Inﬂammation
Research Area, AstraZeneca, Mereside, Alderley Park,
Macclesﬁeld Cheshire SK10 4TG, UK. Tel: 44-1625-513231; Fax:
44-1625-510823; E-mail: rose.maciewicz@astrazeneca.com
Received 6 June 2008; revision accepted 27 September 2008.
782receptor a (ESR1) due to the post-menopausal onset of
OA in females, as well as several genes with reported roles
in cartilage and/or bone metabolism such as: vitamin D re-
ceptor (VDR); asporin (ASPN ); and the interleukin-1 genes
(IL1A, IL1B and IL1RN ). Reports of associations for
variants in these genes have been followed by replication
attempts. However, none of these genes have been consis-
tently conﬁrmed as an OA susceptibility gene. There are
many other potential candidate genes for OA and including
transforming growth factor beta 1 (TGFB1)6, insulin-like
growth factor 1 (IGF1)7,8, interleukin-6 (IL6)9,10 and a disin-
tegrin and metalloproteinase domain 12 (ADAM12)11e13,
which to date have been investigated in one or two studies.
In some cases, an initial negative study that reports no
association for a candidate susceptibility gene may have
deterred further research on that candidate, even though
the initial study design may not have been optimal for dem-
onstrating or refuting an association.
Genetics of OA and Lifestyle (GOAL) is a large well-char-
acterised caseecontrol study of large-joint OA designed for
conducting genetic association analysis and to investigate
geneeenvironment interactions. Our aim was to utilise this
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associations for variants in 12 genes (ADAM12, ASPN,
COL2A1, ESR1, interleukin-4 receptor (IL4R), IGF1, IL1A,
IL1B, IL1RN, IL6, TGFB1 and VDR) with large-joint OA
and to extend our analysis of IGF1, TGFB1, IL1A, IL1B,
IL1RN and IL6. These genes were chosen based on their
having a known or hypothetical association with OA pathol-
ogy (e.g., inﬂammation and tissue remodelling) and/or OA
risk factors (e.g., hormonal status).Patients and methodsSUBJECTSParticipants were men and women recruited from 2002 to 2006 in Notting-
ham into a caseecontrol study (the ‘‘Genetics of OA and Lifestyle’’, or GOAL,
study). Ethics approval was obtained from the Nottingham Research Ethics
Committee.
Knee OA (n¼ 1040) and hip OA (n¼ 1004) cases were recruited from
hospital orthopaedic surgery lists (current and for the previous 5 years)
and from a rheumatology OA clinic. All had been referred to hospital with
symptomatic, clinically severe hip or knee OA and the majority had under-
gone unilateral or bilateral total knee replacement (TKR)/total hip replace-
ment (THR) within the previous 5 years. Subjects were not included in the
study if they had the following: other major arthropathy (e.g., rheumatoid
arthritis, ankylosing spondylitis); Paget’s disease of bone affecting the pelvis
or femur; overt childhood hip disease (e.g., LeggeCalveePerthes disease,
slipped femoral epiphysis, severe acetabular dysplasia); Total joint replace-
ment (TJR) due to hip trauma or avascular necrosis of the femoral head; or
terminal illness. Control subjects were recruited from lists of people who had
attended hospital for intravenous urography (IVU) within the last 5 years. In-
dividuals who had no radiographic evidence of hip OA on their screening IVU
ﬁlm and who had no hip or knee symptoms and none of the exclusions listed
above for cases were invited to take part in the study. Cases and controls
were further characterised by enquiry, examination and investigation.
All participants had radiographs of both knees and the pelvis examined.
The presurgical radiographs of cases who had undergone TJR were copied
using Hipax Dicom digitising software (Hipax, Vorstetten, Germany) to en-
able scoring. If cases and controls had not undergone TJR, new radiographs
were obtained, unless radiographs of the same joint (using the same stand-
ardised method) had been obtained not more than 2 years previously. Pos-
terioreanterior weight-bearing knee radiographs were obtained with the
SynaFlexer positioning frame (Synarc, San Francisco, CA, USA)26, with
feet externally rotated 10, and knees and thighs touching the vertical plat-
form anteriorly and the X-ray beam angled 10 caudally. Skyline 30 views
of both patellofemoral compartments were obtained with the participant
seated, and the beam was angled from feet to knees. Anteroposterior views
of the pelvis were obtained with the participant supine and the feet internally
rotated 10. Knee and pelvis radiographs were all graded for features of OA
by a single investigator. Radiographs were scored for features of radio-
graphic knee or hip OA deﬁned as knee joint space narrowing 2 and/or os-
teophyte score 1, and hip Croft score 3, respectively (for a more detailed
description see Zhang et al.14). Of the 1123 asymptomatic controls, 792 were
free of radiographic signs of OA using these criteria. All knee and hip cases
were conﬁrmed as having radiographic knee and hip OA, respectively. Of the
knee OA cases 78% had undergone TKR and of the hip OA cases 92% had
undergone THR. Of the OA cases 43% had TKR, 47% had THR and 4.3%
had both TKR and THR. Six percent of the hip OA cases had TKR and
3% of the knee OA cases had THR.
Bodymass index (BMI, in kg/cm2) was calculated from height andweight as
measured during the clinical assessment phase of the study, and calcaneal
bone density in g/cm2 (single heel determined by hand dominance) was mea-
sured using DEXA (Norland Apollo 501A00Z). Using information obtained in
the interview-administered questionnaire, social class was determined from
the longest held job usingStandardOccupational Classiﬁcation15 and subjects
were classiﬁed as current smokers, past smokers or never having smoked.GENE AND POLYMORPHISM SELECTIONTwenty previously associated polymorphisms in ADAM12, ASPN,
COL2A1, ESR1, IL4R IGF1, IL1A, IL1B, IL1RN, IL6, TGFB1 and VDR
were selected for genotyping. Forty-eight additional variants spanning
IL1A, IL1B, IL1RN, IL6, IGF1 and TGFB1 were also chosen for further ex-
ploratory analysis. In these genes, Single Nucleotide Polymorphisms
(SNPs) were selected to span the gene with a density of one SNP per
5 kb. For three of the previously associated polymorphisms, a proxy SNP
was genotyped as follows. For IL1A, rs17561 was genotyped in place of
rs1800587 as it had a higher genotyping success rate and was shown to
be in complete linkage disequilibrium (LD), r2¼ 1, with rs1800587 whenboth SNPs were genotyped in a subset of the GOAL controls (n¼ 500).
For IL1RN, rs419598 was genotyped in place of the 86 bp variable number
tandem repeat (VNTR) and for IL6, rs1800797 in place of rs1800795
(174G>C) as they could both be genotyped using TaqMan assays, rather
than by ﬂuorescently labelled polymerase chain reaction (PCR) (IL1RN
VNTR) or sequencing (IL6 rs1800795), and were in LD (r2¼ 0.98 for both
pair-wise comparisons) when genotyped in the subset of GOAL controls
(n¼ 500). All polymorphisms genotyped are detailed in Tables I and II.GENOTYPINGDNA was extracted from whole blood using the Gentra PureGene kit (Qia-
gen). All SNPs were genotyped using the TaqMan platform (Applied Biosys-
tems). Five nanograms of dried DNAwas ampliﬁed in 2 ml reactions containing
TaqManUniversal PCRmastermix (Applied Biosystems) and either assay-by-
design or assay-on-demand primer and probe mixes (Applied Biosystems).
Reactions were cycled on a KBiosystems thermal cycler for 10 min at 92C
followed by 45 cycles of 15 s at 92C and 1 min at 57C. Fluorescence was
detected and genotypes assigned to samples using the ABI7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA, USA).
Fluorescent genotyping was used to type the microsatellite markers. The
aspartic acid repeat of the ASPN gene was ampliﬁed using the following
primers: forward 50 FAM-CACACATCGCACTGAAGAATATG and reverse
50 CCTAAATCTGAGCAATGTACAAC while the promoter repeat of the
IGF1 gene used: forward 50 HEX-GCTGTAAAACCCAACTGAAATAG and
reverse 50 CTAGCCAGCTGGTGTTATTTAG. The PCR products were
then separated on an ABI 3730 DNA analyser and analysed using ABI
GeneMapper software (both from Applied Biosystems).STATISTICAL ANALYSISAnalyses were conducted for each OA phenotype in turn [all OA (i.e.,
knee plus hip, n¼ 2044) was deﬁned as all the cases available to use for
the analysis, hip OA (n¼ 1004) and knee OA (n¼ 1040)], using both all
asymptomatic controls (n¼ 1123) as well as the subset of controls without
radiographic OA (ROA) (n¼ 792), using the STATA v9.2 statistical program
(StataCorp, USA).REPLICATION ANALYSIS OF LITERATURE-ASSOCIATED
POLYMORPHISMSThe 18 SNPs and two microsatellites previously associated with OA were
analysed using the methods described below. Where a polymorphism or
haplotype previously had been reported to be associated with a sub-type
of OA, e.g., female only hip OA, additional analyses were conducted in order
to assess the published association as closely as possible. Details of all tests
replicating those reported in the literature are given in Tables I and II (see
also Supplementary Tables C and D). A positive replication was declared
only if the test for association yielded a P-value 0.05 and the at risk allele,
genotype or haplotype matched that previously published.EXTENDED EXPLORATORY ANALYSIS OF POLYMORPHISMS
IN IGF1, IL1A, IL1B, IL1RN, IL6 AND TGFB1An exploratory analysis of an additional 48 SNPs was also conducted us-
ing the methods described below. A P-value of 0.05 was used as an indi-
cator of potential association. No formal adjustment was made for multiple
testing and the data were considered hypothesis generating to be tested in
future collections.
SNP analysis
Each SNP was analysed in turn. Deviation from HardyeWeinberg equilib-
rium (HWE) was assessed in both sets of control subjects using an exact
test. Logistic regression was used to test for association between allele/ge-
notype frequency and caseecontrol status. For each SNP, an allele-wise
(one degree of freedom (d.f.)) logistic model was ﬁtted, except where evi-
dence (P< 0.05) for deviation from a multiplicative model of inheritance
was observed (assessed at the outset using an independent likelihood ratio
test to compare the ﬁt of the allele-wise (1 d.f.) and genotype-wise (2 d.f.)
models) in which case a genotype-wise (2 d.f.) logistic model was preferred.
All models included adjustment for age (as a continuous variable), gender
and BMI (three World Health Organisation (WHO) categories: normal
<25 kg/m2; overweight 25 to <30 kg/m2; and obese 30 kg/m2). Sensitivity
analyses were conducted to assess the parameterisation of the covariates in
the modelling and no discernable differences were observed. Adjusted allelic
and genotypic odds ratios (ORs) and their corresponding 95% conﬁdence
intervals (CIs) were estimated directly from the ﬁtted models. P-values for as-
sociation were calculated using a likelihood ratio test.
Table I
Previously associated polymorphisms genotyped in the GOAL study and replication analyses conducted in GOAL
Gene dbSNP
identiﬁer
Synonyms bp
change
Control
MAF%
Replication analysis phenotype (Ref.):
Single marker Haplotype
ADAM12 rs3740199 Gly48Arg C>G 45 F knee (11)
ASPN rs5899161 Asn-repeat Knee (20e22)
Hip (21)
M hip/OA (23)
F knee (20)
M knee (20)
COL2A1 rs1635550 C> T 16 M knee (13) M knee (13)
rs2070739 C> T 10 M knee (13)
ESR1 rs2234693 PvuII RFLP T>C 45 F hip (24) F OA (25)
Knee (26,27)
M knee (27)
rs9340799 XbaI RFLP A>G 35 F OA (25)
Knee (26,27)
M knee (27)
rs2228480 BtgI RFLP G>A 20 M knee (27,28),
kee (27)
Knee (27)
M knee (27)
IL4R rs1805013 Ser411Leu C> T 4 F hip (29)
rs1805016 Ser727Ala T>G 5 F hip (29)
VDR rs10735810 FokI RFLP; Met1Thr C> T 38 M knee (28)
rs7975232 ApaI RFLP T>G 46
rs731236 TaqI RFLP; Ile365 T>C 40 F knee (30) M knee (28)
F¼ female, M¼male, MAF¼minor allele frequency, bp¼ base pairs, dbSNP¼NCBI SNP database.
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Microsatellite association analysis was conducted using an allelic test in
CLUMP16. Signiﬁcance of the 2 n table (where n is the number of alleles)
was assessed using a Monte Carlo approach7. Empirical P-values were ob-
tained by running 1000 simulations and counting the number of times the c2
value from the real data was achieved or exceeded by the simulated tables.
Haplotype analysis
Haplotype analyses were conducted using Haploview 4.08. Haplotype
blocks were determined from control genotype data using a conﬁdence
bounds algorithm17. Each haplotype block was tested in turn for association
with OA. In addition, irrespective of the pattern of LD observed in this popu-
lation, association tests were also run on a set of prespeciﬁed haplotype
blocks with the aim of replicating haplotype associations reported in the
literature.Results
Characteristics of the GOAL collection are detailed in
Table III. Approximately 50% of cases and controls were
women. Despite broad frequency-matching of controls to
all cases on age, both the hip and knee cases were older
on average than the controls (when compared to all asymp-
tomatic controls or the subset without ROA), P< 0.001 for
all comparisons. The prevalence of obesity was greater in
cases than controls (P< 0.001) and there were more obese
knee OA cases (54.5%) than obese hip OA cases (39.1%),
P< 0.001. Limiting the controls to the subset without ROA
resulted in a younger and less obese control group. The
prevalence of smoking was lower in both the hip and
knee case groups compared to either control group,
P< 0.001 for all comparisons. Comparing BMI, social class
and smoking prevalence in the asymptomatic control popu-
lation with other UK control or cohort populations of similar
age (including the Health Survey of England 1996, Hertford-
shire Cohort Study and Norfolk EPIC) did not identify any
signiﬁcant differences (data not shown).Two SNPs (rs3783516 in IL1A and rs7975232 in VDR)
were excluded from the analysis due to deviation from
HWE (P< 0.01) in the subset of controls without ROA.REPLICATION ANALYSIS OF LITERATURE-ASSOCIATED
POLYMORPHISMSAccording to our predeﬁned replication criteria, no evi-
dence was found from the initial logistic regression analyses
to conﬁrm the previously reported associations with OA
phenotypes for any of the polymorphisms studied. Where
our initial standard analysis differed from the speciﬁc analy-
sis carried out in the literature report (in terms of the genetic
model or exact phenotype studied), we also repeated that
original analysis as closely as possible, which resulted in
the non-validation of previously reported signiﬁcant associ-
ations for all genes (see Supplementary Tables A and B).
Our results can be summarised as follows, based on the
nominal P-value criterion of 0.05 in our data:
B In IL6, rs1800797 (marker for rs1800795, 174G>C)
did not associate with hip OA as previously reported in
Pola et al.10.
B ADAM12 SNP rs3740199 (Gly48Arg) was not associ-
ated with female knee OA as reported in Valdes et al.11.
B COL2A1 SNP rs1635550 was not associated with male
knee OA as a single SNP or in a haplotype with
rs2070739 as reported in Valdes et al.13.
B For IGF1, comparison of the frequency of the 194 bp
allele of the CA repeat to the other alleles in subjects
under 65 years old did not detect the association re-
ported by Meulenbelt et al.7 with neither OA, hip OA
nor knee OA.
B In ESR1, rs228480 (BtgI) and rs234693 (PvuII) did not
associate with knee OA in males as reported by Jin
et al.27 and hip OA in females as reported by Lian
et al.24, respectively. Replication haplotype analysis
Table II
Polymorphisms genotyped in exploratory analysis of IGF1, IL1 genes, IL6 and TGFB1 in the GOAL study and replication analyses conducted
in GOAL
Gene dbSNP identiﬁer Synonyms bp change Control MAF% Replication analysis, OA phenotype (Ref.):
Single marker Haplotype
IGF1 rs2946834 C> T 32
rs6219 G> A 9
rs6220 T>C 28
rs1520220 G>C 17
rs5742665 G>C 14
rs972936 G> A 26
rs7136446 A>G 42
rs2033178 C> T 6
rs4764697 G> A 27
Novelx A> T 3
rs2195239 G>C 23
rs1019731 G> T 14
rs17796225 A>G 25
rs12821878 C> T 23
rs5742615 C>A 2
rs10665874 Promoter msat Knee/hip/OA (7)
rs35767 C> T 15
rs35765 C>A 11
IL1A rs10496445 C> T 31
rs3783516 G> A 40
rs17561* 889T>C G> T 30 Knee (31)
rs2048874 G> A 13
IL1B rs13032029 G> A 45
rs1143623 G>C 26
rs16944 511C> T C> T 32 Hip (18) Hip (18), knee (32)
rs1143633 5810G>A G> A 35
rs1143634 3954C> T C> T 25 Hip (18) Hip (18), knee (32)
IL1RN rs17669228 C> T 22
rs1542176 C> T 50
rs1688075 A>C 7
rs17207494 A>C 39
rs315920 C> T 21
rs315919 G> T 40
rs3213448 G> A 14
rs419598y 8006T>C T>C 27 Hip (18) Hip (18), knee (32)
rs315952 11100T>C T>C 30 Knee (32)
rs3087270 A>G 30
rs315943 A>G 39
rs895495 G> A 32
IL6 rs4719714 A> T 23
rs1800797z 174G>C G> A 41 Hip (10)
rs1800796 G>C 5
rs2069860 A> T 1
rs2140543 G>C 30
TGFB1 rs4803457 G> A 37
rs1800468 G> A 8
rs1800469 C> T 30
rs1982073 Leu10Pro T>C 37 F spine OAx (33)
rs11466321 T>C 8
rs4803455 T>G 50
rs8110090 T>C 6
rs2278422 G>C 42
rs11466343 G> A 4
rs8105161 A>G 17
rs8179181 C> T 23
rs2241718 C> T 19
F¼ female, MAF¼minor allele frequency, bp¼ base pairs, dbSNP¼NCBI SNP database.
*Marker for rs1800587.
yMarker for 86 bp VNTR.
zMarker for rs1800795.
xNot spinal osteophytosis.
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Fig. 1. Pair-wise LD between IL1B and IL1RN SNPs used in haplo-
type analysis in the subset of controls without ROA. Colour denotes
pair-wise D 0 values and numbers note pair-wise r2 values.
rs1143634 and rs16944 are in IL1B. rs419598 and rs315952 are
in IL1RN. No haplotype blocks were deﬁned using the conﬁdence
bounds method17.
Table III
Characteristics of the GOAL study participants
Asymptomatic controls Controls without ROA All OA cases Hip OA cases Knee OA cases
N 1123 792 2044 1004 1040
Gender
Female 522 (46.5%) 386 (48.7%) 1012 (49.5%) 507 (50.5%) 505 (48.6%)
Male 601 (53.5%) 406 (51.3%) 1032 (50.5%) 497 (49.5%) 535 (51.4%)
Age (years)
MeanSD 64.3 8.4 62.7 8.4 67.9 7.3 67.7 7.1 68.1 7.4
BMI (kg/m2)
<25 348 (31.0%) 271 (34.2%) 292 (14.3%) 193 (19.2%) 99 (9.5%)
25< 30 488 (43.5%) 328 (41.4%) 792 (38.7%) 418 (41.6%) 374 (36.0%)
30 287 (25.6%) 193 (24.4%) 960 (47.0%) 393 (39.1%) 567 (54.5%)
Smoking
Never 399 (35.5%) 272 (34.3%) 858 (42.0%) 399 (39.7%) 459 (44.1%)
Ex-smoker 494 (44.0%) 339 (42.8%) 979 (47.9%) 501 (49.9%) 478 (46.0%)
Current 230 (20.5%) 181 (22.9%) 207 (10.1%) 104 (10.4%) 103 (9.9%)
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ciation with female generalised OA (Ushiyama et al.25)
or knee OA (Bergink et al.26). Haplotype analysis of
rs234693, rs9340799 and rs2228480 did not replicate
the association with knee OA and male knee OA re-
ported by Jin et al.27.
B The association between IL1A SNP rs17561 (marker
for rs1800587, 889T>C) and knee OA reported by
Loughlin et al.31 was not signiﬁcantly replicated.
B The associations between IL1B SNPs (rs1143634 and
rs16944) and the IL1RN VNTR (here a marker
rs419598 was used in analysis) and hip OA in Meulen-
belt et al.18 were not signiﬁcantly replicated here.
B Haplotype analysis was conducted to attempt to repli-
cate the signiﬁcant ﬁndings of Meulenbelt et al.18 and
Smith et al.32, A haplotype comprised of rs16944
(IL1B), rs1143634 (IL1B) and rs419598 (marker SNP
for IL1RN VNTR) was not associated with hip OA as
previously reported18 nor was the haplotype of the
same three SNPs plus rs315952 (IL1RN ) associated
with knee OA as previously reported32. It is worth not-
ing that LD across the IL1 genes is low and that the
SNPs used in this and previous analyses did not lie
within the same LD block when examining LD in the
control population (Fig. 1).
B For IL1RN, there was some evidence that the T allele of
rs315952 was associated with an increased risk for OA
overall and for hip OA, OR¼ 1.14 (1.01e1.29)
P¼ 0.032 and OR¼ 1.15 (1.00e1.32) P¼ 0.05, respec-
tively, when comparing cases to all asymptomatic con-
trols. Virtually identical results were seen using subset
of controls without ROA, although a small reduction in
power was observed when analysing this subset
(P¼ 0.051 and P¼ 0.054 for OA and hip OA, respec-
tively) due to the decrease in control sample size. Similar
increased risks were also observed for the knee OA phe-
notype; although the evidence for association in these
analyses was again reduced when limiting the analysis
to the controls free of ROA (see Supplementary Table
B). This SNP has only been associated previously with
OA in the literature as part of a haplotype, but this haplo-
type was not associated with OA phenotypes in GOAL.
B In IL4R, rs1805013 and rs1805016 were not associated
with hip OA in females as reported by Forster et al.29.
B rs1982073 (Leu10Pro) in TGFB1 was not associated
with OA in females as reported in Yamada et al.33.However, the previous reported association was with
spinal osteophytosis not OA.
B In VDR, rs731236 was not associated with knee OA in
females as reported by Keen et al.30. Haplotype analy-
sis of rs10735810 and rs731236 and knee OA in males
was not signiﬁcant as reported by Valdes et al.13,28.
However, again LD was low between the two SNPs
(D0 ¼ 0.02, r2¼ 0.00, in ROA free controls) included in
the haplotype analysis.EXTENDED EXPLORATORY ANALYSIS OF POLYMORPHISMS
IN IGF1, IL1A, IL1B, IL1RN, IL6 AND TGFB1In the further exploratory analysis of TGFB1 we found ev-
idence to suggest that two SNPs may be associated with
OA phenotypes, however, the strength of evidence differed
according to the controls used (Table IV).
Table IV
Significant results from exploratory analysis of IGF1, IL1 genes, IL6 and TGFB1
Gene SNP Phenotype Genotype or
allele comparison
Asymptomatic controls Controls without ROA
OR (95%CI) Adjusted
P-value
OR (95%CI) Adjusted
P-value
IGF1 rs2195239 Hip OA G vs C 1.18 (1.01, 1.37) 0.034 1.17 (0.99, 1.39) 0.072
IL1RN rs315920 Knee OA C vs T 1.18 (1.00e1.39) 0.049 1.16 (0.96e1.39) 0.131
TGFB1 rs2278422* OA CG vs GG 0.77 (0.64e0.91) 0.004 0.86 (0.71, 1.06) 0.26
CC vs GG 0.99 (0.78e1.24) 1.01 (0.77, 1.32)
rs2278422* Knee OA CG vs GG 0.69 (0.56e0.85) 0.001 0.78 (0.62e0.99) 0.10
CC vs GG 0.94 (0.71e1.23) 0.95 (0.70e1.30)
rs8179181 Knee OA T vs C 1.11 (0.95e1.29) 0.180 1.22 (1.03e1.45) 0.02
*Deviation from HWE in asymptomatic controls (P¼ 0.005).
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rs2278422 was associated with reduced risk of OA
(P¼ 0.004) and knee OA (P¼ 0.001) when the analysis in-
cluded all asymptomatic controls, among whom the SNP
signiﬁcantly deviated from HWE (P¼ 0.005). However,
there was no association with OA when comparing cases
to the subset of controls without ROA, in whom there was
no deviation from HWE (P¼ 0.31). In knee OA there re-
mained some evidence of a reduced risk in heterozygotes
but the genotype-wise likelihood ratio test was not signiﬁ-
cant (P¼ 0.10). The T allele of TGFB1 rs8179181 was
associated with increased risk of knee OA, but in this
case only when the analysis was restricted to the subset
of controls without ROA.
In IL1RN the C allele of rs315920 was signiﬁcantly asso-
ciated with increased risk of knee OA in the analysis using
all asymptomatic controls. Limiting the analysis to the sub-
set of controls without ROA resulted in loss of signiﬁcance
(P¼ 0.131), although the point estimates remained similar.
A single SNP in IGF1 rs2195239 was associated with in-
creased risk for hip OA (OR¼ 1.18 (1.01e1.37) P¼ 0.034)
when comparing cases to asymptomatic controls, but the
evidence for association was reduced when the analysis
was limited to controls without ROA (P¼ 0.072).
No signiﬁcant associations were identiﬁed in the further
exploratory analysis of IL1A, IL1B and IL6 using either
control group.Discussion
In this study we attempted to replicate previously reported
genetic associations with OA. We did not ﬁnd statistically
signiﬁcant evidence at the 0.05 level to support the reported
associations with OA, hip OA or knee OA in any of the 12
studied genes for the tested polymorphisms. Attempting to
replicate the putative associations by using the same af-
fected joint, gender, genetic model and adjusting for the
same confounders also provided no clear evidence to sup-
port these ﬁndings. However, our extended exploratory
analysis of six of the 12 genes did provide some evidence
of association with OA for four other polymorphisms; two
SNPs in TGFB1, one SNP in IGF1 and one SNP in IL1RN.
Reasons for a lack of replication could be due to: differ-
ences in case ascertainment and phenotype criteria; geno-
typing different and too few markers; differences in
ethnicity; and the occurrence of false positives in the initial
studies or false negatives in the replication study. Insufﬁ-
cient power related to sample size, is a likely source of false
positives in initial studies, which consequently tend toover-estimate genetic effects (‘‘winners curse’’)19. Limited
power to detect genetic associations is a signiﬁcant prob-
lem in studying genetics of any complex disease. GOAL
has a reasonable sample size, larger than the majority of
published OA genetic association studies, and therefore,
has greater power to detect associations, although it may
still be of insufﬁcient size to detect very modest effect sizes
or effects of rarer alleles.
Not all previous studies have included X-rays assess-
ments of control subjects, so the prevalence of ROA in
these studies is unknown. Therefore, it is possible that the
heterogeneity in control ascertainment and assessment
may explain some inconsistent results across study popula-
tions. Indeed the degree of association in our extended ex-
ploratory analysis of TGFB1, IGF1 and IL1RN, was
dependant on the control group used. We were able to
undertake such a comparison as a high percentage of our
control population had asymptomatic ROA (30%), mainly
of the knee. Limiting the analysis to controls without ROA
diminished the evidence for association for some polymor-
phisms compared to that using all asymptomatic controls,
although in many cases similar OR point estimates were
obtained. For example, rs2195239 in IGF1 associated
with an increased risk of hip OA but this only reached signif-
icance when all asymptomatic controls were included,
although the OR point estimates were similar in the two
analyses (Table IV). This may in part be explained by a re-
duction in power due to the reduced sample size when only
X-ray negative controls were used. In contrast, reducing the
heterogeneity in phenotype may increase the likelihood of
detecting a true association and more accurately predict
its effect size despite the reduction in sample size. For
instance, we found the T allele of rs8179181 in TGFB1 to
associate with a greater increased risk of knee OA when
comparing cases to the subset of controls without ROA
rather than all the asymptomatic controls. This effect would
have gone undetected if the analysis had not been
restricted to the subset of controls without ROA.
What constitutes an appropriate control population for OA
genetics studies remains unclear. This may depend on the
role of the gene being investigated e.g., genes important in
OA pain may be detected using controls with asymptomatic
OA but genes important in joint structural changes, e.g.,
cartilage destruction, may only be detected when the con-
trols have no ROA. Another problem is how to deﬁne cases
and controls given that OA presents a continuous spectrum
of disorder rather than an all or none phenomenon. Addi-
tionally, because of the late onset and high prevalence of
OA individuals may be controls at one time-point but then
subsequently develop OA and become cases in later
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an age and gender matched asymptomatic control group
and assessing for the presence of ROA. Finally as the initi-
ation and progression of OA is multi-factorial and depen-
dent on multiple genetic and environmental/lifestyle
factors, ﬁnding signiﬁcant association and understanding
genetic mechanisms may also require geneegene and
geneeenvironment interaction analyses, or at least
accounting for environmental factors in some way. Our
results comparing the use of asymptomatic controls or
asymptomatic, radiographic-free controls should be noted
for future researchers to consider in their study design.
In the OA genetic literature there are also examples of
haplotype association studies. In some instances the poly-
morphisms combined in the analysis are not in strong LD
with one another and, therefore, do not form haplotype
blocks as deﬁned by the conﬁdence bounds method17 or
similar methods. For example, polymorphisms in IL1B and
IL1RN have been combined in previous analysis although
examination of LD in the GOAL control population indicated
they were not in the same haplotype block. All attempts in
this study to replicate reported haplotype analysis, whether
using appropriately combined polymorphisms into LD-
based haplotypes or otherwise, did not produce any
evidence of association with OA.
There are limitations to the current study. It is unknown
whether there is any underlying population stratiﬁcation in
the population, although this would seem unlikely as all
subjects were Caucasian and recruited from a relatively
homogenous geographically well-deﬁned area. However,
the control recruitment method may have resulted in an
increased prevalence of individuals with other diseases,
such as kidney-related diseases and subsequent shared
genetic factors. An additional limitation is that our ascer-
tainment may have introduced a selection bias of controls
and cases towards ‘‘extreme’’ normals and severe (end
stage) symptomatic and ROA. Use of radiographic deﬁni-
tions of OA may reduce this bias but in itself generates
new limitations. Furthermore, in the analysis presented
here, we have chosen to deﬁne the case based on the
initial clinical diagnosis. However, subsequent radio-
graphic scoring indicates that some individuals have
ROA at both the hip and knee. As is it not possible to ret-
rospectively determine if this is a secondary or co-primary
event we have chosen to use the primary diagnosis. Fi-
nally, repeating our analysis using both deﬁnitions of an
OA control (asymptomatic with and without ROA) adds
to the number of tests conducted. Viewed in the context
of multiple testing it is likely that some of the results gen-
erated from our exploratory analysis represent false pos-
itives ﬁndings, therefore, the hypotheses generated need
to be tested in other cohorts.
In conclusion, we were unable to statistically validate
a number of reported associations with OA. Further explor-
atory analysis of some genes detected associations where
statistical signiﬁcance was dependent on the size and
deﬁnition of the control group used. Consequently these
analyses generated hypotheses that require testing in an in-
dependent data set. While the GOAL cohort is a relatively
large OA case and control cohort and can be used to under-
take replication analysis with high precision and validity, for
various reasons i.e., failure to exactly duplicate previous
study designs, our results cannot provide a ﬁnal answer.
Such judgements will depend on thorough evaluation of
all available present and future results, including appropri-
ate use of meta-analysis. It is clear from the ﬁndings re-
ported here that large, well-deﬁned cohorts of OA casesand controls are required to detect and validate genetic as-
sociations in order for the genetic component of OA to be
fully elucidated.Conﬂict of interest
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